← Back to Search

Behavioural Intervention

Smoking Cessation + Pain Management Program for Cancer Survivors

Phase 4
Recruiting
Led By Kathryn I Pollak, PhD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Report pain within the last 3 weeks of 3 or higher on a 10 point scale
Age 18 or older
Must not have
Hearing impaired
Evidence of unstable cognitive or mental health problems who cannot properly provide consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Summary

This trial will test a program to help cancer survivors quit smoking and reduce pain.

Who is the study for?
This trial is for cancer survivors over 18 who have smoked at least 100 cigarettes in their lifetime, currently smoke 5+ a day, and are experiencing pain. They should be willing to quit smoking, not in another cessation study, speak English, diagnosed with cancer within the last 5 years and have a life expectancy of at least one year.
What is being tested?
Project HOPES aims to test a new program designed for cancer survivors that combines smoking cessation support with pain management. The intervention includes Varenicline—a medication used to help people stop smoking—and other strategies tailored for individuals dealing with both issues.
What are the potential side effects?
Varenicline can cause nausea, sleep disturbances (like insomnia or vivid dreams), constipation, gas and/or vomiting. Some may experience changes in taste or dry mouth. It's important to note that side effects vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have experienced pain of 3 or more on a scale of 10 in the last 3 weeks.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have hearing difficulties.
Select...
I am able to understand and give consent for my treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of patients who complete the study
Number of patients who report that the intervention was helpful
Secondary study objectives
Change in patient-reported pain (severity, interference)
Change in patient-reported quality of life (Coping)
Change in patient-reported quality of life (Depression/Mood/Negative Affect)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Study populationExperimental Treatment2 Interventions
All patients will receive a smoking cessation and pain management intervention combined with clinician-prescribed varenicline.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Varenicline
2011
Completed Phase 4
~4170

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,424 Previous Clinical Trials
3,066,064 Total Patients Enrolled
Kathryn I Pollak, PhDPrincipal InvestigatorDuke University
3 Previous Clinical Trials
1,910 Total Patients Enrolled
~13 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top